Syncom Formulations (India) (524470) Stock Overview
Manufactures, markets, and sells pharmaceutical formulation products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 524470 from our risk checks.
524470 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Syncom Formulations (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹19.51 |
| 52 Week High | ₹22.52 |
| 52 Week Low | ₹10.21 |
| Beta | 0.80 |
| 1 Month Change | 30.76% |
| 3 Month Change | 34.74% |
| 1 Year Change | 8.51% |
| 3 Year Change | 126.07% |
| 5 Year Change | 221.42% |
| Change since IPO | 1,198.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524470 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.1% | 0.2% | -1.4% |
| 1Y | 8.5% | 14.5% | -1.2% |
Return vs Industry: 524470 underperformed the Indian Pharmaceuticals industry which returned 14.5% over the past year.
Return vs Market: 524470 exceeded the Indian Market which returned -1.2% over the past year.
Price Volatility
| 524470 volatility | |
|---|---|
| 524470 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: 524470 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524470's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 744 | n/a | www.syncomformulations.com |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and suspensions, creams, gel, ORS, jelly, gynae, inhalers, opthal, ortho, and pediatrics formulations in dosage forms.
Syncom Formulations (India) Limited Fundamentals Summary
| 524470 fundamental statistics | |
|---|---|
| Market cap | ₹18.34b |
| Earnings (TTM) | ₹855.30m |
| Revenue (TTM) | ₹4.98b |
Is 524470 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524470 income statement (TTM) | |
|---|---|
| Revenue | ₹4.98b |
| Cost of Revenue | ₹2.81b |
| Gross Profit | ₹2.17b |
| Other Expenses | ₹1.31b |
| Earnings | ₹855.30m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.91 |
| Gross Margin | 43.56% |
| Net Profit Margin | 17.18% |
| Debt/Equity Ratio | 0.4% |
How did 524470 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 06:39 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syncom Formulations (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.